Skip to main content

Table 5 Satisfaction with the decision process 1 by perceived role and by concordance

From: Patient participation in decisions about disease modifying anti-rheumatic drugs: a cross-sectional survey

  Perceived role   Concordance  
  Doctor Shared Patient P2 Too little participation Enough participation Too much participation P3
Mean Mean Mean Mean Mean Mean
(SD) (SD) (SD) (SD) (SD) (SD)
MDM in general (N = 502) 4.0a 4.2a 4.0 .04* 3.9ab 4.2a 4.4b .00**
(0.8) (0.7) (0.6) (0.8) (0.7) (0.5)
(N = 218) (N = 278) (N = 6) (N = 142) (N = 302) (N = 52)
Traditional DMARD (N = 332) 3.9a 4.2a 4.3 .00** 3.8ab 4.1a 4.3b .00**
(0.7) (0.6) (0.5)   (0.6) (0.6) (0.7)
(N = 234) (N = 90) (N = 8) (N = 177) (N = 141) (N = 12)
Injecting MTX (N = 137) 3.8a 4.2a 4.0 .02* 3.7ab 4.1a 4.3b .00**
(0.9) (0.6) (0.7) (0.8) (0.7) (0.7)
(N = 53) (N = 59) (N = 25) (N = 41) (N = 76) (N = 20)
Biologic agent (N = 131) 4.0 4.3 4.2 .16 4.1 4.3 3.8 .31
(0.8) (0.6) (1.6) (0.9) (0.7) (1.2)
(N = 58) (N = 67) (N = 6) (N = 39) (N = 80) (N = 10)
Decrease/stop (N = 304) 3.9a 4.1ab 3.8b .00** 3.8a 4.1ab 3.8b .00**
(0.8) (0.6) (0.8) (0.8) (0.7) (0.8)
(N = 115) (N = 115) (N = 74) (N = 80) (N = 139) (N = 84)
  1. MDM = Medical Decision-making; DMARD = Disease Modifying Anti-Rheumatic Drug; MTX = methotrexate.
  2. 1ranging from 1 – 5 in which higher scores indicate more satisfaction.
  3. 2p-levels for differences between doctor, shared and patient, tested with the Kruskal-Wallis test.
  4. 3p-levels for differences between too little, enough and too much participation, tested with the Kruskal-Wallis test.
  5. a or bDistributions are significant different from each other (post hoc test with Mann Whitney with Bonferroni correction).
  6. *Significant on the .05 level.
  7. **Significant on the .01 level.